medigraphic.com
Instituto Nacional de Salud Pública

2022, Number 4

<< Back Next >>

salud publica mex 2022; 64 (4)

Cervical cancer screening programs in Latin America: current recommendations for facing elimination challenges

Fernández-Deaza G, Caicedo-Martinez M, Serrano B, Roura E, Castillo JS, de Sanjose S, Bruni L, Murillo R

Language: English
References: 37
Page: 415-423
PDF size: 392.51 Kb.


ABSTRACT

Objective. To describe current cervical cancer screening program guidelines in Latin America. Materials and methods. We searched official recommendations for the general population and women living with HIV (WLHIV) by reviewing official sources from 19 countries; these data were supplemented with a consultation carried out by the WHO with the Ministries of Health. Results. Screening policies vary significantly in regard to target populations, primary tests, and screening intervals. Sixteen countries have recently updated their recommendations; however, cytology remains the primary screening test for most countries. Eleven countries have introduced HPV tests, and eight countries have implemented screen-and-treat algorithms; only three countries have developed evidence-based guidelines. All countries but Costa Rica have specific recommendations for WLHIV. Conclusions. Although most countries have updated their screening policies, only a few are properly aligned with the WHO elimination strategy. Recommendations for WLHIV require better integration with cervical cancer screening programs.


REFERENCES

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence andMortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin.

  2. 2021;71(3):209-49. https://doi.org/10.3322/caac.216602. World Health Organization. Draft: Global Strategy towards the eliminationof cervical cancer as a public health program. Geneva: WHO, 2020 [cited2020 Jun 8]. Available from: https://www.who.int/publications/m/item/draft-global-strategy-towards-eliminating-cervical-cancer-as-a-public-health-problem

  3. Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al.Impact of HPV vaccination and cervical screening on cervical cancerelimination: a comparative modelling analysis in 78 low-income and lowermiddle-income countries. Lancet. 2020;395(10224):575-90. https://doi.org/10.1016/S0140-6736(20)30068-4

  4. International Agency for Research on Cancer. Global Cancer Observatory.Lyon: International Agency for Research on Cancer, 2020 [cited 2021Jan 29]. Available from: https://gco.iarc.fr/

  5. Almonte M, Murillo R, Sánchez GI, González P, Ferrera A, Picconi MA, etal. Multicentric study of cervical cancer screening with human papillomavirustesting and assessment of triage methods in Latin America: theESTAMPA screening study protocol. BMJ Open. 2020;10(5):e035796.https://doi.org/10.1136/bmjopen-2019-035796

  6. Murillo R, Herrero R, Sierra MS, Forman D. Cervical cancer in Centraland South America: Burden of disease and status of disease control. CancerEpidemiol. 2016;44(1):S121-30. https://doi.org/10.1016/j.canep.2016.07.015

  7. World Health Organization, Pan American Health Organization.Cancer country profiles. OMS, PAHO, 2020 [cited2022 Jan 12]. Available from: https://www3.paho.org/hq/index.php?option=com_docman&view=list&slug=4-cancer-country-profiles-2020&Itemid=270&lang=es

  8. World Health Organization. Comprehensive Cervical Cancer Control. Aguide to essential practice. Geneva: WHO, 2014 [cited 2020 Sep 3]. Availablefrom: https://www.who.int/reproductivehealth/publications/cancers/cervical-cancer-guide/en/

  9. de Sanjose S, Holme F. What is needed now for successful scale-up ofscreening? Papillomavirus Res. 2019;7:173-5. https://doi.org/10.1016/j.pvr.2019.04.011

  10. Pan American Health Organization. Plan of action for cervicalcancer prevention and control 2018-2030. Washington DC: PAHO,2018 [cited 2020 Jun 8]. Available from: https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=mandatesstrategies-3448&alias=47584-plan-cervical-cancer-2018-2030&Itemid=270&lang=en

  11. Lynge E, Törnberg S, von Karsa L, Segnan N, van Delden JJM. Determinantsof successful implementation of population-based cancer screeningprogrammes. Eur J Cancer. 2012;48(5):743-8. https://doi.org/10.1016/j.ejca.2011.06.051

  12. Murillo R. Social inequalities in cancer in Latin America. In: Vaccarella S,Lortet-Tieulent J, Saracci R, Conway DI, Straif K, Wild CP, editors. Reducingsocial inequalities in cancer: Evidence and priorities for research. Lyon: IARCScientific Publication, 2019:223-6 [cited 2020 Jun 8]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Iarc-Scientific-Publications/Reducing-Social-Inequalities-In-Cancer-Evidence-And-Priorities-For-Research-2019

  13. Instituto Nacional de Câncer, Ministério da Saúde. Diretrizes Brasileiraspara o Rastreamento do Câncer do Colo do Útero. Rio de Janeiro:Inca, 2016 [cited 2020 Jun 8]. Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//diretrizesparaorastreamentodocancerdocolodoutero_2016_corrigido.pdf

  14. Ministerio de Salud. Guías Clínicas AUGE, Cáncer Cérvico Uterino.Santiago: Minsal, 2015 [cited 2020 Jun 8]. Available from: https://www.minsal.cl/wp-content/uploads/2015/09/GPC-CaCU.pdf

  15. Ministerio de Salud y Protección Social. Guía de Práctica Clínica parala detección y manejo de lesiones precancerosas de cuello uterino. Colombia:Ministerio de Salud y Protección Social, 2014 [cited 2022 Jan 12].Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/CA/gpc-lesiones-precancerosas-cuello-uterino-padres.pdf

  16. Secretaría de Salud. Programa de Acción Específico 2007-2012. Cáncercervicouterino. Mexico City: Secretaría de Salud, 2008 [cited 2020 Jun8]. Available from: http://www.cnegsr.salud.gob.mx/contenidos/descargas/CaCu/pae_cacu.pdf

  17. Secretaría de Salud. Programa de acción específico, prevención ycontrol del cáncer de la mujer 2013-2018. Mexico City: Secretaría deSalud, 2014 [cited 2020 Jun 8]. Available from: https://www.gob.mx/cms/uploads/attachment/file/10046/PrevencionyControldelCancerdelaMujer_2013_2018.pdf

  18. Ministerio de Salud, Coordinación Nacional de Salud Sexual y Reproductiva.Normas de prevención, detección y seguimiento de las lesionespreinvasoras del cuello uterino y guías de manejo. Panamá: Ministerio deSalud, 2017 [cited 2020 Jun 8]. Available from: http://www.minsa.gob.pa/sites/default/files/programas/normas_de_prevencion_cacu.pdf

  19. Arrossi S, Thouyaret L, Paul L. Prevención del cáncer cervicouterino. Recomendacionespara el tamizaje, seguimiento y tratamiento de mujeres enel marco de programas de tamizaje basados en el test de VPH: actualización.Buenos Aires: Instituto Nacional del Cáncer Argentina, 2015 [cited 2020Jun 8]. Available from: https://bancos.salud.gob.ar/sites/default/files/2018-10/0000000017cnt-manual_recomendaciones_tamizaje_2015_baja.pdf

  20. Secretaría de Salud. Protocolo para el tamizaje y tratamiento de lesionespremalignas para la prevención del cáncer cervicouterino. Honduras:Secretaría de Salud, 2015 [cited 2022 Jan 12]. Available from: https://extranet.who.int/ncdccs/Data/HND_D1_Protocolo%20C%C3%A1ncer%20C%C3%A9rvicouterino%20(30%20NOV).pdf

  21. Ministerio de Salud Pública y Asistencia Social. Guía de atención integralpara la prevención, detección y tratamiento de lesiones precursorasdel cáncer cérvico uterino. Guatemala: Ministerio de Salud Pública yAsistencia Social, 2020 [cited 2021 Feb 17]. Available from: https://osarguatemala.org/guia-de-atencion-integral-para-la-prevencion-deteccion-ytratamiento-de-lesiones-precursoras-del-cancer-cervico-uterino/

  22. Fernández-Deaza G, Caicedo-Martínez M, Serrano B, Roura E, Castillo JS,Silvia de S, et al. Appendix A and B. Figshare 2022. Available from: https://doi.org/10.6084/m9.figshare.20235681.v1

  23. World Health Organization, International Agency for Research onCancer, Working Group on the Evaluation of Cancer Preventive Agents.Cervix cancer screening. IARC Handbooks of Cancer Prevention. Lyon:IARC Press, 2005 [cited 2020 Jun 8]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-Prevention/Cervix-Cancer-Screening-2005

  24. Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-HirschPP, Mustafa RA, et al. Cytology versus HPV testing for cervical cancerscreening in the general population. Cochrane Database Syst Rev.2017;8(8):CD008587. https://doi.org/10.1002/14651858.CD008587.pub2

  25. Chrysostomou A, Stylianou D, Constantinidou A, Kostrikis L. CervicalCancer Screening Programs in Europe: The Transition Towards HPV Vaccinationand Population-Based HPV Testing. Viruses. 2018;10(12):729. https://doi.org/10.3390/v10120729

  26. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK,Barry MJ, Caughey AB, et al. Screening for Cervical Cancer: US PreventiveServices Task Force Recommendation Statement. JAMA. 2018;320(7):674-86. https://doi.org/10.1001/jama.2018.10897

  27. Canadian Task Force on Preventive Health Care. Recommendationson screening for cervical cancer. CMAJ. 2013;185(1):35-45. https://doi.org/10.1503/cmaj.121505

  28. Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervicalprecancer and reaching underscreened women by using HPV testing onself samples: updated meta-analyses. BMJ. 2018;363:k4823. https://doi.org/10.1136/bmj.k4823

  29. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P,Velasco-Mondragón E, et al. Self-collection of vaginal specimens for humanpapillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet. 2011;378(9806):1868-73.https://doi.org/10.1016/S0140-6736(11)61522-5

  30. Arrossi S, Thouyaret L, Herrero R, Campanera A, Magdaleno A, CuberliM, et al. Effect of self-collection of HPV DNA offered by communityhealth workers at home visits on uptake of screening for cervicalcancer (the EMA study): a population-based cluster-randomised trial.Lancet Glob Health. 2015;3(2):e85-94. https://doi.org/10.1016/S2214-109X(14)70354-7

  31. Holme F, Jerónimo J, Maldonado F, Camel C, Sandoval M, Martínez-Granera B, et al. Introduction of HPV testing for cervical cancer screeningin Central America: The Scale-Up project. Prev Med. 2020;135:106076.https://doi.org/10.1016/j.ypmed.2020.106076

  32. Frenk J, Gómez-Dantés O. Health Systems in Latin America: TheSearch for Universal Health Coverage. Arch Med Res. 2018;49(2):79-83.https://doi.org/10.1016/j.arcmed.2018.06.002

  33. Joint United Nations Programme on HIV/AIDS. Seazing the Moment;tackling entrenched inequalities to end epidemics. Geneva: UNAIDS, 2020[cited 2020 Oct 5]. Available from: https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf

  34. Joint United Nations Programme on HIV/AIDS. HIV estimates withuncertainty bounds from 1990-present. Geneva: UNAIDS, 2021 [cited2022 Jan 12]. Available from: https://www.unaids.org/en/resources/documents/2021/HIV_estimates_with_uncertainty_bounds_1990-present

  35. Mohammed D, Shukla P, Babayants Y, Sison R, Slim J. Increased proportionsof HIV-infected women met cervical cancer screening guideline in 2016. Int JWomens Health. 2018;10:83-7. https://doi.org/10.2147/IJWH.S153003

  36. Abraham AG, D’Souza G, Jing Y, Gange SJ, Sterling TR, Silverberg MJ, et al.Invasive cervical cancer risk among HIV-infected women: a North Americanmulticohort collaboration prospective study. Acquir Immune Defic Syndr.2013;62(4):405-13. https://doi.org/10.1097/QAI.0b013e31828177d7

  37. World Health Organization. WHO guidelines for screening andtreatment of precancerous lesions for cervical cancer prevention. Geneva:WHO, 2013 [cited 2020 Oct 5]. Available from: https://apps.who.int/iris/bitstream/handle/10665/94830/9789241548694_eng.pdf




2020     |     www.medigraphic.com